(Q40484548)

20 September 2017

title

Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab (English)

1 reference

angioimmunoblastic T-cell lymphoma

20 September 2017

main subject

1 reference

Stephanie Halene

1

1 reference

20 September 2017

Arthur Zieske

series ordinal

2

1 reference

20 September 2017

Nancy Berliner

series ordinal

3

1 reference

20 September 2017

publication date

1 March 2006

1 reference

Nature Clinical Practice Oncology

20 September 2017

published in

1 reference

20 September 2017

volume

3

1 reference

20 September 2017

issue

3

1 reference

20 September 2017

page(s)

165-8; quiz 169

1 reference

Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

7 January 2021

Angio-immunoblastic lymphadenopathy with dysproteinaemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

7 January 2021

Updated Kiel classification for lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

7 January 2021

Angioimmunoblastic T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

7 January 2021

Angioimmunoblastic T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

7 January 2021

T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

7 January 2021

Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0430

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0430

1 reference

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC0430

1 reference

7 January 2021

Identifiers

DOI

10.1038/NCPONC0430

1 reference

20 September 2017

1 reference